Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Garfield Heights, Ohio Clinical Trials

A listing of Garfield Heights, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (33) clinical trials

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

This is a signal seeking Phase I/II 6-month, randomized, double-blind placebo-controlled trial of everolimus in individuals, ages 5 to 45 years with a PTEN mutation, with safety and neurocognition as the primary endpoints. Participant's or a legal guardian will need to sign an informed consent prior to enrollment in the ...

Phase

4.52 miles

Learn More »

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

The primary objective of the Single-Dose Phase is to assess the pharmacokinetics (PK) and safety of single doses of NI-03 when administered at doses of 100 mg, 200 mg or 300 mg to subjects with chronic pancreatitis. The primary objective of the Double-Blind Phase of the study is to determine ...

Phase

5.42 miles

Learn More »

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties (pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness of TOFA administrated to young adults (18-45 years) with moderately to severely active SLE-CL. Subjects will be studied at the Cincinnati Children's Hospital Medical Center (CCHMC) and recruited locally. ...

Phase

5.42 miles

Learn More »

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and ...

Phase

5.42 miles

Learn More »

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

MCL is a rare subtype of non-Hodgkin lymphoma that is considered incurable with conventional therapy. For relapsed patients, Ibrutinib, lenalidomide, and bortezomib are all approved by the FDA but are not curative. Novel approaches are required to improve outcomes for patients with relapsed/refractory MCL. This is an open-label study that ...

Phase

5.42 miles

Learn More »

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency

This is a Phase 1/2, open-label, single arm, multicenter, safety and dose finding study of DTX301 in adults with late-onset OTC deficiency. The primary objective of the study is to determine the safety of single IV doses of DTX301. Eligible subjects will receive a single IV infusion of DTX301. Dose ...

Phase

6.32 miles

Learn More »

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody ...

Phase

6.32 miles

Learn More »

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

This is a multicenter, open-label safety study to determine the dose regimen of SYNT001 administered intravenously in subjects with pemphigus (vulgaris or foliaceus).

Phase

6.32 miles

Learn More »

CD40 Agonistic Antibody APX005M in Combination With Nivolumab

APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase followed by a Phase 2 tumor specific portion. Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first. Study ...

Phase

6.32 miles

Learn More »

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX ...

Phase

6.32 miles

Learn More »